GlassScriptPhysician profile
Nancy Tactuk Romanenko
NPI 1699923102
$20,526.01
in general payments reported to CMS, 2019-2025
46 companies · $3,463 in 2025
The $3,463 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,440 · 2020: $2,535 · 2021: $2,979 · 2022: $3,065 · 2023: $3,161 · 2024: $2,883 · 2025: $3,463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,499 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,498.63 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,563.79 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $2,187.86 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,720.04 | 2019-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $1,511.14 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $1,257.41 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $1,175.30 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $856.27 | 2020-2025 | |
| Amarin Pharma, INC. | $829.75 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $785.25 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $744.07 | 2019-2025 | Xifaxan, Trulance |
| Allergan, INC. | $720.01 | 2019-2021 | |
| Astellas Pharma US INC | $644.68 | 2019-2023 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $629.50 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $571.40 | 2019-2025 | Jardiance, Ofev, Spiriva Respimat |
| Sumitomo Pharma America, INC. | $382.31 | 2023-2025 | Gemtesa |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Tactuk Romanenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.